FDA

IGI, a Clinical-Stage Oncology Biotech, Reveals Initial Results from Groundbreaking Trispecific TREAT Antibody Study Based in New York, Ichnos Glenmark Innovation (IGI), a prominent clinical-stage biotech company known for its multispecific developments in the oncology sector, has revealed the initial […]

To enhance the precision of liquid medication dosing and streamline patient treatment processes, Honeywell has unveiled a cutting-edge liquid flow sensing system. Applicable across a variety of fields—from medical liquid management and wearable drug delivery to in vitro diagnostics—the innovative

In alignment with its Corporate Social Responsibility (CSR) commitments, Dr Reddy’s Lab based in Hyderabad has partnered with Kakinada Engineering Alumni Trust Services (KEATS) to bolster infrastructure at the Andhra Pradesh Tribal Welfare Residential College of Excellence (for girls) and

Merck, recognized as MSD outside the US and Canada, has unveiled significant progress with its phase 3 KEYLYNK-001 clinical trial. This study examined the efficacy of Keytruda (pembrolizumab) combined with chemotherapy, succeeded by maintenance therapy with Lynparza (olaparib), with or

Medigene AG, a company specializing in oncology platforms aimed at the exploration and advancement of T cell receptor-directed therapies for cancer treatment, has unveiled its choice of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, under the context of HLA

IDEAYA Biosciences, Inc., a leader in precision oncology, has unveiled the nomination of its development candidate, IDE892, a prospective leading MTA-cooperative PRMT5 inhibitor. “We are thrilled to broaden our precision oncology portfolio with the nomination of our 7th development candidate,

Roche has shared results from a pivotal five-year follow-up study on the phase III POLARIX trial, which assesses the efficacy of Polivy (polatuzumab vedotin) alongside MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP), for treating newly diagnosed diffuse large B-cell lymphoma

Endo, Inc., a leading specialty pharmaceutical enterprise, has secured approval from the US Food and Drug Administration (FDA) to commence the commercial production of Vasostrict (vasopressin injection, USP) at their latest state-of-the-art aseptic manufacturing plant in Indore, India. Spanning over